Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

The approval of the first kinase inhibitor, imatinib, for the treatment of chronic myelogenous leukemia (CML) in 2001 and the success of antibody-based drugs that targeted the epidermal growth ...